BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 27566487)

  • 1. The Role of the Microenvironment in Prostate Cancer-Associated Bone Disease.
    Turner CJ; Edwards CM
    Curr Osteoporos Rep; 2016 Oct; 14(5):170-7. PubMed ID: 27566487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone-targeted therapies to reduce skeletal morbidity in prostate cancer.
    Dorff TB; Agarwal N
    Asian J Androl; 2018; 20(3):215-220. PubMed ID: 29553053
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metastatic Prostate Cancer and the Bone: Significance and Therapeutic Options.
    Gartrell BA; Coleman R; Efstathiou E; Fizazi K; Logothetis CJ; Smith MR; Sonpavde G; Sartor O; Saad F
    Eur Urol; 2015 Nov; 68(5):850-8. PubMed ID: 26153564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of bone metastases in prostate cancer: a review.
    Bienz M; Saad F
    Curr Opin Support Palliat Care; 2015 Sep; 9(3):261-7. PubMed ID: 26262831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Basic and clinical associations between bone and cancer.
    He F; Matsumoto Y
    Immunol Med; 2020 Sep; 43(3):103-106. PubMed ID: 32301686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone-targeting agents in prostate cancer.
    Suzman DL; Boikos SA; Carducci MA
    Cancer Metastasis Rev; 2014 Sep; 33(2-3):619-28. PubMed ID: 24398856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent advances in bone-targeted therapies of metastatic prostate cancer.
    Deng X; He G; Liu J; Luo F; Peng X; Tang S; Gao Z; Lin Q; Keller JM; Yang T; Keller ET
    Cancer Treat Rev; 2014 Jul; 40(6):730-8. PubMed ID: 24767837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bone Health and Bone-targeted Therapies for Prostate Cancer: a Programme in Evidence-based Care - Cancer Care Ontario Clinical Practice Guideline.
    Alibhai SMH; Zukotynski K; Walker-Dilks C; Emmenegger U; Finelli A; Morgan SC; Hotte SJ; Winquist E;
    Clin Oncol (R Coll Radiol); 2017 Jun; 29(6):348-355. PubMed ID: 28169118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting bone metastases in prostate cancer: improving clinical outcome.
    Body JJ; Casimiro S; Costa L
    Nat Rev Urol; 2015 Jun; 12(6):340-56. PubMed ID: 26119830
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current trials using bone-targeting agents in prostate cancer.
    Tu SM; Lin SH
    Cancer J; 2008; 14(1):35-9. PubMed ID: 18303481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Examining the metastatic niche: targeting the microenvironment.
    Guise T
    Semin Oncol; 2010 Oct; 37 Suppl 2():S2-14. PubMed ID: 21111245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging drugs for the treatment of bone metastasis.
    Pantano F; Iuliani M; Zoccoli A; Fioramonti M; De Lisi D; Fioroni I; Ribelli G; Santoni M; Vincenzi B; Tonini G; Santini D
    Expert Opin Emerg Drugs; 2015; 20(4):637-51. PubMed ID: 26113304
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interactions between cancer cells and bone microenvironment promote bone metastasis in prostate cancer.
    Zhang X
    Cancer Commun (Lond); 2019 Nov; 39(1):76. PubMed ID: 31753020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging therapies in bone metastasis.
    Clément-Demange L; Clézardin P
    Curr Opin Pharmacol; 2015 Jun; 22():79-86. PubMed ID: 25935860
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A multi-targeted approach to treating bone metastases.
    Camacho DF; Pienta KJ
    Cancer Metastasis Rev; 2014 Sep; 33(2-3):545-53. PubMed ID: 24390423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dynamic modeling of bone metastasis, microenvironment and therapy: Integrating parathyroid hormone (PTH) effect, anti-resorptive and anti-cancer therapy.
    Coelho RM; Lemos JM; Alho I; Valério D; Ferreira AR; Costa L; Vinga S
    J Theor Biol; 2016 Feb; 391():1-12. PubMed ID: 26657065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Skeletal-related events in prostate cancer.
    Smith MR
    Clin Adv Hematol Oncol; 2012 Aug; 10(8):535-6. PubMed ID: 23073052
    [No Abstract]   [Full Text] [Related]  

  • 18. Bone targeted therapies in metastatic castration-resistant prostate cancer.
    Rajpar S; Fizazi K
    Cancer J; 2013; 19(1):66-70. PubMed ID: 23337759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The effect of bisphosphonates on bone metastasis of hormone-refractory prostate cancer].
    Tanaka T; Kawashima H; Kuratsukuri K; Sugimura K; Nakatani T
    Hinyokika Kiyo; 2006 Jun; 52(6):491-4. PubMed ID: 16848364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Encounter of cancer cells with bone. Management of bone metastasis arising from prostate cancer].
    Kamoto T
    Clin Calcium; 2011 Mar; 21(3):465-71. PubMed ID: 21358069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.